Consensus-Based Expert Recommendations for Diagnosis and Clinical Management of Vanishing White Matter.
СтатьяОбзорConsensus StatementНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
van Voorst Romy J, Schoenmakers Daphne H, Bonkowsky Joshua L, Vanderver Adeline, Krägeloh-Mann Ingeborg, Bernard Geneviève, Bertini Enrico, Fatemi Ali, Sgobbi Paulo V, Wolf Nicole I, Groeschel Samuel, Tonduti Davide, Sevin Caroline, Orthmann-Murphy Jennifer L, Schöls Ludger, Salsano Ettore, Brais Bernard, Jaffe Nicole, Ter Horst Kasper W, Hannema Sabine E, Hayes Katherine G, Meyburg Jochen, van Heerde Marc, Sbrocchi Anne Marie, van Spaendonk Rosalina, Thiffault Isabelle, Hofsteenge Geesje H, Sudmeier-Broek Carolina, Timmer Corrie, Skwirut Donna, Buck Allyson, Hollberg Bret, Chapleau Ron, Dekker Hanka, Campbell Susan G, Abbink Truus E M, Leferink Prisca S, van der Knaap Marjo S
Аннотация
Vanishing white matter (VWM) is a rare disorder, characterized by degeneration of CNS white matter, clinically often exacerbated by stressors such as fever and minor head trauma. VWM is caused by biallelic pathogenic variants in the EIF2B1-5 genes, causing reduced activity of eukaryotic initiation of translation factor 2B, resulting in dysregulation of the integrated stress response (ISR). New scientific insights and increased clinical trials in experimental therapies highlight the need for clinical guidelines to improve and standardize care for patients with VWM worldwide. Standardized care is important for therapy development, as it lessens clinical variability of trial participants at study entry, enabling more sensitive evaluation of treatment outcomes. The aim of this study was to develop expert consensus-based recommendations for diagnosis and management of VWM. A real-time Delphi process with a multidisciplinary expert panel was conducted to formulate consensus-based recommendations. A literature review was performed to determine the strength of available evidence supporting each recommendation. The consensus yielded 43 recommendations on diagnosis, including genetic and MRI criteria, and on clinical management concerning disease progression, acute and long-term care, and preventive strategies. All known pathogenic and likely pathogenic EIF2B1-5 variants were identified from the literature and Amsterdam Leukodystrophy Center laboratory. An overview of these EIF2B1-5 variants was composed to facilitate diagnosis. Clinically used drugs may activate the ISR, posing a risk in VWM, or have no effect on or suppress the ISR, being probably safe in VWM. A second literature search explored the effects of clinically frequently used drugs on the ISR. Drugs were categorized into those likely to activate the ISR, suppress it, and have no likely effects on the ISR. Final judgment was achieved in a consensus meeting of experts. A patient management card was developed with input from clinical experts and patient advocates to provide information on these consensus-based recommendations in lay language and bridge the gap between scientific evidence and expert opinion on one side and the practical needs of clinicians and families on the other side. This study contributes to improving and standardizing VWM care based on scientific and expert insights, while highlighting key areas for future research.